Patents by Inventor Joel Morris

Joel Morris has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11365211
    Abstract: Methods for stereoselective synthesis and manufacturing of 2?-deoxynucleosides, such as 2?-ribonucleosides, are disclosed. In some embodiments, the 2?-deoxynucleoside is a ?-anomer of a 2?-deoxynucleoside having a 3? ? hydroxyl, 4? ? hydroxymethyl configuration. Nonlimiting examples of compounds prepared by the disclosed methods include 4?-thio-2?-deoxycytidine (T-dCyd) and 5-aza-4?-thio-2?-deoxycytidine (5-aza-T-dCyd; aza-T-dCyd; aza-T-dC).
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: June 21, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Lianhao Zhang, Baburao Vishnuvajjala, Joel Morris, Robert Bahde, Sergiy M. Denysenko, Omar Diego Lopez, Donn Gregory Wishka
  • Patent number: 11254662
    Abstract: Halogenated analogs of 5-aza-2?-deoxycytidine, such as halogenated analogs of 5-aza-4?-thio-2?-deoxycytidine (5-aza-T-dCyd) are described. Pharmaceutical compositions including a halogenated analog and methods of using the halogenated analogs to inhibit neoplasia are described.
    Type: Grant
    Filed: June 9, 2021
    Date of Patent: February 22, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Joel Morris, Donn G. Wishka, Omar Diego Lopez
  • Publication number: 20220033387
    Abstract: Halogenated analogs of 5-aza-2?-deoxycytidine, such as halogenated analogs of 5-aza-4?-thio-2?-deoxycytidine (5-aza-T-dCyd) are described. Pharmaceutical compositions including a halogenated analog and methods of using the halogenated analogs to inhibit neoplasia are described.
    Type: Application
    Filed: September 23, 2019
    Publication date: February 3, 2022
    Applicant: The USA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Joel Morris, Donn G. Wishka, Omar Diego Lopez
  • Publication number: 20210292310
    Abstract: Halogenated analogs of 5-aza-2?-deoxycytidine, such as halogenated analogs of 5-aza-4?-thio-2?-deoxycytidine (5-aza-T-dCyd) are described. Pharmaceutical compositions including a halogenated analog and methods of using the halogenated analogs to inhibit neoplasia are described.
    Type: Application
    Filed: June 9, 2021
    Publication date: September 23, 2021
    Applicant: The USA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Joel Morris, Donn G. Wishka, Omar Diego Lopez
  • Publication number: 20200361977
    Abstract: Methods for stereoselective synthesis and manufacturing of 2?-deoxynucleosides, such as 2?-ribonucleosides, are disclosed. In some embodiments, the 2?-deoxynucleoside is a ?-anomer of a 2?-deoxynucleoside having a 3? ? hydroxyl, 4? ? hydroxymethyl configuration. Nonlimiting examples of compounds prepared by the disclosed methods include 4?-thio-2?-deoxycytidine (T-dCyd) and 5-aza-4?-thio-2?-deoxycytidine (5-aza-T-dCyd; aza-T-dCyd; aza-T-dC).
    Type: Application
    Filed: January 30, 2019
    Publication date: November 19, 2020
    Applicants: The USA, as represented by the Secretary, Department of Health and Human Services, Alchem Laboratories Corporation
    Inventors: Lianhao Zhang, Baburao Vishnuvajjala, Joel Morris, Robert Bahde, Sergiy M. Denysenko, Omar Diego Lopez, Donn Gregory Wishka
  • Publication number: 20130152438
    Abstract: A method for promoting individual support, affiliation or allegiance, including printing a message on an elastic loop, wherein the message is decompressed and fully legible when the elastic loop is stretched and wherein the message is compressed and not fully legible when the elastic loop is unstretched, and distributing the elastic loop to a wearer. The elastic loop is sized to be stretched when worn on the wearer's wrist, such that the message is expanded into an uncompressed and legible configuration.
    Type: Application
    Filed: June 18, 2012
    Publication date: June 20, 2013
    Inventor: Joel Morris
  • Publication number: 20120204457
    Abstract: A method for promoting individual support, affiliation or allegiance, including printing a message on an elastic loop, wherein the message is decompressed and fully legible when the elastic loop is stretched and wherein the message is compressed and not fully legible when the elastic loop is unstretched, and distributing the elastic loop to a wearer. The elastic loop is sized to be stretched when worn on the wearer's wrist, such that the message is expanded into an uncompressed and legible configuration.
    Type: Application
    Filed: February 10, 2011
    Publication date: August 16, 2012
    Inventor: Joel Morris
  • Patent number: 7585869
    Abstract: The invention relates to compounds of formula 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R1, R3, R4, R11, N, Z, A, m and p are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula 1 and to pharmaceutical compositions for treating such disorders which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.
    Type: Grant
    Filed: May 20, 2004
    Date of Patent: September 8, 2009
    Assignee: Pfizer, Inc.
    Inventors: Samit Kumar Bhattacharya, Jinshan Chen, Richard Damian Connell, John Charles Kath, Goss S. Kauffman, Blaise S. Lippa, Joel Morris
  • Publication number: 20090111805
    Abstract: The invention relates to compounds of the formula I: and to pharmaceutically acceptable salts and solvates thereof, wherein X, Z, V, W, R4, R5, R6, R7, and ring B are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula I and to pharmaceutical compositions for treating such disorders which contain the compounds of formula I. The invention also relates to methods of preparing the compounds of formula I.
    Type: Application
    Filed: February 15, 2006
    Publication date: April 30, 2009
    Inventors: Joel Morris, Blaise Scott Lippa, Gonghua Pan, Goss Stryker Kauffman, Chao Li
  • Publication number: 20080051419
    Abstract: The invention relates to compounds of formula I: or a pharmaceutically acceptable salt thereof, wherein: A is a moiety of formula: and to pharmaceutically acceptable salts and solvates thereof, wherein X, Z, D, E, V, W, Y, R1, R2, R5, R6, L, and u are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula I to a patient in need thereof, and to compositions for treating such disorders which contain the compounds of formula I. The invention also relates to methods of making the compounds of formula I.
    Type: Application
    Filed: July 20, 2007
    Publication date: February 28, 2008
    Inventors: Matthew Corbett, Kevin Freeman-Cook, Goss Kauffman, Blaise Lippa, Michael Luzzio, Joel Morris
  • Patent number: 7332493
    Abstract: The invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R1, R3, R4, R5, R11, m and p are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula 1 and to pharmaceutical compositions for treating such disorders which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.
    Type: Grant
    Filed: March 14, 2005
    Date of Patent: February 19, 2008
    Assignee: OSI Pharmaceuticals
    Inventors: John Charles Kath, Joel Morris, Samit Kumar Bhattacharya
  • Patent number: 7276602
    Abstract: The invention relates to compounds of the formula 1 or pharmaceutically acceptable salts, prodrugs, solvates or hydrates thereof, wherein wherein X, R1, and R2 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formula 1.
    Type: Grant
    Filed: July 24, 2003
    Date of Patent: October 2, 2007
    Assignee: Pfizer Inc
    Inventors: Blaise Lippa, Tricia Ann Kwan, Joel Morris, Susan D. LaGreca, Matthew David Wessel
  • Publication number: 20060193400
    Abstract: A dual adaptive importance-sampling system and method is provided that can estimate the probability of events by combining dual complementary importance-sampling simulations. The present invention exploits the ability to determine an optimal biased pdf using an iterative procedure that requires relatively little a priori knowledge of how to bias. Hence, the present invention is particularly suited for evaluating the BERs and/or WERs of coded communication and storage systems, and is generally applicable to arbitrarily chosen codes. When applied to coded communication and storage systems, the present invention provides a versatile technique for the fast and accurate estimation of BERs and WERs of FEC codes down to values of 10?20 or lower.
    Type: Application
    Filed: July 14, 2004
    Publication date: August 31, 2006
    Inventors: Joel Morris, Ronald Holzloehner, Amitkumar Mahadevan, Curtis Menyuk, John Zweck
  • Patent number: 6927220
    Abstract: The invention relates to 6- or 7-bicyclic-substituted 4-amino-subsituted pyridopyrimidines and to pharmaceutically acceptable salts, prodrugs and hydrates thereof. The invention also relates to pharmaceutical compositions containing the compounds and to methods of treating hyperproliferative disorders abnormal cell growth in a mammal by administering the compounds.
    Type: Grant
    Filed: April 12, 2002
    Date of Patent: August 9, 2005
    Assignee: Pfizer Inc
    Inventors: Joel Morris, Samit K. Bhattacharya, John C. Kath
  • Publication number: 20050159435
    Abstract: The invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R1, R3, R4, R5, R11, m and p are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula 1 and to pharmaceutical compositions for treating such disorders which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.
    Type: Application
    Filed: March 14, 2005
    Publication date: July 21, 2005
    Inventors: John Kath, Joel Morris, Samit Bhattacharya
  • Patent number: 6890924
    Abstract: The invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R1, R3, R4, R5, R11, m and p are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula 1 and to pharmaceutical compositions for treating such disorders which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.
    Type: Grant
    Filed: June 18, 2001
    Date of Patent: May 10, 2005
    Assignee: Pfizer Inc
    Inventors: John Charles Kath, Joel Morris, Samit Kumar Bhattacharya
  • Publication number: 20040242604
    Abstract: The invention relates to compounds of formula 1 1
    Type: Application
    Filed: May 20, 2004
    Publication date: December 2, 2004
    Applicant: Pfizer Inc
    Inventors: Samit Kumar Bhattacharya, Jinshan Chen, Richard Damian Connell, John Charles Kath, Goss S. Kauffman, Blaise S. Lippa, Joel Morris
  • Publication number: 20040152691
    Abstract: The invention relates to compounds of the formula 1 1
    Type: Application
    Filed: July 24, 2003
    Publication date: August 5, 2004
    Applicant: Pfizer Inc
    Inventors: Blaise Lippa, Tricia Ann Kwan, Joel Morris, Susan D. LaGreca, Matthew David Wessel
  • Publication number: 20030186995
    Abstract: The invention relates to compounds of the formula 1 1
    Type: Application
    Filed: January 21, 2003
    Publication date: October 2, 2003
    Applicant: Pfizer Inc.
    Inventors: John Charles Kath, Tom Norma Jacqueline, Liu Zhengyu, Eric David Cox, Joel Morris, Samit Kumar Bhattacharya
  • Patent number: 6541481
    Abstract: The invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts and solvates thereof, wherein A, X, R1, R3 and R4 are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals with administering the compounds of formula 1 and to pharmaceutical compositions for treating such disorders which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.
    Type: Grant
    Filed: April 12, 2001
    Date of Patent: April 1, 2003
    Assignee: Pfizer Inc
    Inventors: John Charles Kath, Norma Jacqueline Tom, Zhengyu Liu, Eric David Cox, Joel Morris, Samit Kumar Bhattacharya